<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03847909</url>
  </required_header>
  <id_info>
    <org_study_id>DCR-PHXC-201</org_study_id>
    <nct_id>NCT03847909</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2</brief_title>
  <acronym>PHYOX2</acronym>
  <official_title>A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dicerna Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dicerna Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of DCR-PHXC in Children and
      Adults with Primary Hyperoxaluria Type 1 (PH1) and Primary Hyperoxaluria Type 2 (PH2)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-weighted standardized (TWS) area under the curve (AUC) of percent change from baseline in 24-hour urinary oxalate excretion between Day 90 and Day 180</measure>
    <time_frame>3 months (Last 3 months of the 6 month treatment period)</time_frame>
    <description>Four measurements of percent change from baseline in 24-hour urinary oxalate are combined to determine a single AUC value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TWS AUC of percent change from baseline in 24-hour urinary oxalate-to-creatinine ratio (value/upper limit of normal [ULN]) between Day 90 and Day 180</measure>
    <time_frame>3 months (Last 3 months of the 6 month treatment period)</time_frame>
    <description>Four measurements of percent change from baseline in 24-hour urinary oxalate-to-creatinine ratio are combined to determine a single AUC value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with a 24-hour Uox level &lt; 0.46 mmol/24 hours or ≥ 0.46 - &lt; 0.60 mmol/24 hours at at least two consecutive study visits commencing at Day 90 and ending at Day 180</measure>
    <time_frame>At least 2 months starting at Day 90 and through Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with 24-hour Uox levels in each of 4 quartile ranges (&lt; 1.1 mmol, 1.1 to &lt; 1.6 mmol, 1.6 to ≤ 2.4 mmol, and &gt; 2.4 mmol/24 hours from baseline to Day 180</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TWS AUC of percent change from baseline in 24-hour urinary oxalate-to-creatinine ratio (value/upper limit of normal [ULN]) between baseline and Day 180</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TWS AUC of percent change from baseline in plasma oxalate</measure>
    <time_frame>3 months (Last 3 months of the 6 month treatment period)</time_frame>
    <description>Four measurements of percent change from baseline in plasma oxalate are combined to determine a single AUC value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse events (AE) from baseline to study completion</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of serious adverse events (SAE) from baseline to study completion</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Primary Hyperoxaluria Type 1 (PH1)</condition>
  <condition>Primary Hyperoxaluria Type 2 (PH2)</condition>
  <condition>Kidney Diseases</condition>
  <condition>Urologic Diseases</condition>
  <condition>Genetic Disease</condition>
  <arm_group>
    <arm_group_label>DCR-PHXC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention, drug, DCR-PHXC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Sterile Normal Saline (0.9% NaCl)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, sterile normal saline (0.9% NaCl) for subcutaneous (SC) injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DCR-PHXC</intervention_name>
    <description>Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection</description>
    <arm_group_label>DCR-PHXC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterile Normal Saline (0.9% NaCl)</intervention_name>
    <description>Sterile Normal Saline (0.9% NaCl) for subcutaneous (SC) injection, administered at same injection volume as DCR-PHXC, to serve as placebo</description>
    <arm_group_label>Placebo - Sterile Normal Saline (0.9% NaCl)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Willing to provide written informed consent or assent

          -  Confirmation of PH1 and PH2 disease

          -  Must meet the 24 hour urine oxalate excretion requirements

             - Page 3 of 5 -

          -  Estimated GFR at screening ≥ 30 mL/min normalized to 1.73 m2 BSA

        Key Exclusion Criteria:

          -  Renal or hepatic transplantation (prior or planned within the study period)

          -  Currently on dialysis or anticipated requirement for dialysis during the study period

          -  Documented evidence of clinical manifestations of systemic oxalosis

          -  Use of an RNA interference (RNAi) drug within the last 6 months

          -  Participation in any clinical study in which you received an investigational medicinal
             product (IMP) within 4 months before Screening

          -  Liver function test (LFT) abnormalities: Alanine aminotransferase (ALT) and/or
             aspartate aminotransferase (AST) &gt;1.5 times upper limit of normal (ULN) for age and
             gender

          -  Unwillingness to comply with study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Info</last_name>
    <phone>617-621-8097</phone>
    <email>medicalinfo@dicerna.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Parkville</city>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Hamilton</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>9103102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Białystok</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Santa Cruz</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 15, 2019</study_first_submitted>
  <study_first_submitted_qc>February 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PH1</keyword>
  <keyword>PH2</keyword>
  <keyword>Primary Hyperoxaluria</keyword>
  <keyword>RNAi</keyword>
  <keyword>RNAi therapeutic</keyword>
  <keyword>GalNAc</keyword>
  <keyword>LDHA gene</keyword>
  <keyword>LDH</keyword>
  <keyword>siRNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Hyperoxaluria, Primary</mesh_term>
    <mesh_term>Urologic Diseases</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

